Artelo biosciences completes positive pre-ind meeting with fda for art26.12

Solana beach, calif., sept. 07, 2023 (globe newswire) -- artelo biosciences, inc.  (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced it has completed a pre-ind (investigational new drug) meeting with the u.s. food and drug administration (fda) regarding the manufacturing, preclinical and clinical development plan for art26.12.
ARTL Ratings Summary
ARTL Quant Ranking